Ph3 of Vepugratinib + Enfortumab Vedotin + Pembrolizumab in Urothelial Carcinoma FGFR3 (FORAGER 2)
Phase III Clinical Trial
J4G-MC-JZVD: FORAGER-2 (JZVD: Ph 3 Randomized Double-blind Placebo-controlled Multicenter Study of LOXO-435(LY3866288)) in combination with Enfortumab Vedotin plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 genetic alteration.
Participating Locations